Prevalence and Influencing Factors of Depression in Patients with Parkinson’s Disease

,; Li, Ling; Wang, Zhengyang; ,; You, Zhifei; ,; Huang, Jing; ,

doi:10.5152/alphapsychiatry.2023.231253

Cited by 6 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PD is pathologically characterized by the loss of dopaminergic neuron in the substantia nigra (SN) and the presence of α-synuclein protein accumulation. PD has a prevalence in people aged 65 and above of about 1.7% (Li et al, 2023 ). One study has predicted that by 2030, the number of PD patients will reach 4.94 million in China, accounting for about 50% of the global incidence (Yue et al, 2024 ).…”

Section: Introductionmentioning

confidence: 99%

Early dopaminergic replacement treatment initiation benefits motor symptoms in patients with Parkinson's disease

Li,

Dong,

Dong

et al. 2024

Front. Hum. Neurosci.

View full text Add to dashboard Cite

BackgroundParkinson's disease (PD) generally progresses slowly, but it is controversial whether delaying treatment accelerates the progression.ObjectiveDetermine the correlation between the time of dopaminergic replacement treatment initiation and the severity of clinical symptoms in PD, including motor and non-motor symptoms.MethodsPD patients were divided between 155 people who were diagnosed de novo and 165 PD patients receiving dopamine replacement therapy. Basic patient characteristics included gender, age, age at onset, disease duration, and the time of dopaminergic replacement treatment initiation. We used MDS-UPDRS scores to evaluate the severity of motor symptoms and we also used the scale to assess the severity of non-motor symptoms such as cognition, mood, sleep, and quality of life.ResultsThe mean time between symptom onset and the initiation of drug treatment was 31.0 (22.5) months. After adjusting for age, sex, age at onset, and disease duration, we found that the MDS-Unified Parkinson's Disease Rating Scale (UPDRS)-III score increased faster in the de novo group with a similar disease duration (F = 8.7, p = 0.0034) than the treatment group. The cumulative incidence of progression to H-Y score 3 in de novo PD group over disease duration was 39.7% in 50months and 92.2% in 100 months, while in treated group such cumulative incidence was 15.5% in 50 months, 51.4% in 100 months and 81.5% in 150 months. The cumulative incidence of patients in the de novo PD group was higher than that in the treated group (p = 0.001), suggesting that untreated patients were more likely to progress to the advanced stages. Symptoms onset, the time between symptom onset and treatment initiation, age, sex, and disease duration explained 28.95% of the total variation in the MDS-UPDRS-III score for motor symptoms. In drug-naïve patients, the time between symptom onset and treatment initiation explained 20.1% of the total variation in the MDS-UPDRS-III score for motor symptoms (t = 6.15, p < 0.001).ConclusionsThese data in our study showed that early dopaminergic replacement treatment have played a positive role in PD patients, while dopaminergic replacement delayed treatment might be detrimental to motor symptoms and non-motor state of PD patient. Recognizing early stage symptoms of PD and early diagnosis are of great significance to treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Early dopaminergic replacement treatment initiation benefits motor symptoms in patients with Parkinson's disease

Li,

Dong,

Dong

et al. 2024

Front. Hum. Neurosci.

View full text Add to dashboard Cite

show abstract

New insights into the effects of serotonin on Parkinson's disease and depression through its role in the gastrointestinal tract

Sancho-Alonso,

Sarriés-Serrano,

Miquel-Rio

et al. 2024

Spanish Journal of Psychiatry and Mental Health

View full text Add to dashboard Cite

Relationship of Glymphatic Function with Cognitive Impairment, Sleep Disorders, Anxiety and Depression in Patients with Parkinson’s Disease

Gui,

Meng,

Shen

et al. 2024

NDT

View full text Add to dashboard Cite

Introduction Previous studies have predominantly explored the relationship of the glymphatic system with motor symptoms in Parkinson’s disease (PD); however, research on non-motor symptoms remains limited. Therefore, this study investigated the association between glymphatic function and non-motor symptoms, including cognitive impairment and sleep disorders, in PD patients. Methods This study recruited 49 PD patients and 38 healthy controls (HC). Glymphatic function was evaluated using enlarged perivascular spaces (EPVS) in the basal ganglia (BG) region and diffusion tensor image analysis along the perivascular space (DTI-ALPS) index. Cognition, sleep, anxiety, and depression scales were assessed in all participants. According to the scale scores, PD patients were further divided into several groups to identify the presence of non-motor symptoms. Differences in EPVS numbers and ALPS index between PD subgroups and HC group were compared. Spearman correlation analysis was performed to investigate the association between the PD non-motor symptoms and ALPS index. Additionally, receiver operating characteristic (ROC) curves analysis was conducted for ALPS index to predict cognitive impairment and insomnia in PD patients. Results PD patients with and without non-motor symptoms all showed more EPVS numbers than the controls, and the EPVS numbers in PD patients with cognitive impairment were also greater than those without. Notably, except for the depression subgroup, PD patients with non-motor symptoms showed significantly lower ALPS index than the controls. The Montreal Cognitive Assessment (MoCA) scores were positively correlated, whereas the Parkinson’s Disease Sleep Scale (PDSS)-2 and REM Sleep Behavior Disorder Screening Questionnaire (RBDSQ) scores were negatively correlated with the ALPS index in PD patients (r=0.3618, P=0.0053; r=−0.4146, P=0.0015; r=−0.2655, P=0.0326, respectively). The ALPS index proved to be predictive of cognitive impairment and insomnia in PD patients (AUC=0.7733, P=0.001; AUC=0.7993, P=0.0004, respectively). Conclusion Glymphatic function is closely associated with cognition and sleep of PD patients.

show abstract

Prevalence and Influencing Factors of Depression in Patients with Parkinson’s Disease

Cited by 6 publications

References 23 publications

Early dopaminergic replacement treatment initiation benefits motor symptoms in patients with Parkinson's disease

Early dopaminergic replacement treatment initiation benefits motor symptoms in patients with Parkinson's disease

New insights into the effects of serotonin on Parkinson's disease and depression through its role in the gastrointestinal tract

Relationship of Glymphatic Function with Cognitive Impairment, Sleep Disorders, Anxiety and Depression in Patients with Parkinson’s Disease

Contact Info

Product

Resources

About